Introduction {#Sec1}
============

Together with *Haemophilus influenzae* and *Moraxella catarrhalis*, *Streptococcus pneumoniae* is a main causative organism of otorhinolaryngological infections and respiratory tract infections in children. *S. pneumoniae* in particular is a major causative organism for sepsis and purulent meningitis after infancy, and it is considered to be one of the most important bacterial strains causing infections \[[@CR1], [@CR2]\].

In recent years, the increase in penicillin-intermediate *S. pneumoniae* (PISP) and penicillin-resistant *S. pneumoniae* (PRSP), which show resistance to penicillins, is becoming a problem. It has also been reported that sensitivity to cephems and carbapenems is decreasing, which is a factor in making respiratory tract and otorhinolaryngological infections in children more intractable and their treatment more difficult \[[@CR3]\].

Amid the trend of increasing resistance of *S. pneumoniae*, our group has surveyed drug sensitivity over time since 2000. The results of nationwide surveys conducted in 2007 (period 3) and 2010 (period 4), following earlier surveys in 2000--2001 (period 1) and 2004 (period 2) \[[@CR4]\], are now reported.

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

Among the strains clinically isolated from children with meningitis, sepsis, and respiratory infection at 27 facilities that participated in the nationwide Drug-Resistant Pathogen Surveillance Group in Pediatric Infectious Disease between January and June 2007 (period 3) and January and June 2010 (period 4), 283 strains and 459 strains were investigated in each period, respectively, that were judged by the physicians in charge to be causative organisms based on the amount of bacteria, laboratory test, and patients' clinical symptoms.

The number of strains isolated from various specimens was calculated in each period, and the following results were obtained: blood (7 strains), swabs collected from the nasopharynx (251 strains), sputum (21 strains), ear discharge (1 strain), and unknown (3 strains) in period 3, and blood (23 strains), spinal fluid (1 strain), swabs collected from the nasopharynx (392 strains), sputum (41 strains), and unknown (2 strains) in period 4.

In addition, to determine the origin of each strain, factors such as sex, age, presence or absence of siblings, presence or absence of group childcare, presence or absence of previous treatment with antibacterial agents, and the location of the hospital were investigated. The present study was reviewed and approved by the ethics committee of each facility in accordance with their regulations.

Measured drugs {#Sec4}
--------------

In testing sensitivity, 21 drugs were used in period 3 \[penicillin G (PCG), ampicillin (ABPC), amoxicillin (AMPC), cefaclor (CCL), cefditoren (CDTR), cefcapene (CFPN), cefpodoxime (CPDX), cefdinir (CFDN), cefotiam (CTM), ceftriaxone (CTRX), cefotaxime (CTX), cefteram (CFTM), azithromycin (AZM), clarithromycin (CAM), rokitamycin (RKM), faropenem (FRPM), panipenem (PAPM), meropenem (MEPM), vancomycin (VCM), telithromycin (TEL), and levofloxacin (LVFX)\]; and 24 drugs were used in period 4 \[PCG, ABPC, AMPC, piperacillin (PIPC), CCL, CDTR, CFPN, CPDX, CFDN, CTM, CTRX, CTX, CFTM, AZM, CAM, RKM, FRPM, PAPM, MEPM, doripenem (DRPM), tebipenem (TBPM), VCM, LVFX, and tosufloxacin (TFLX)\].

Sensitivity testing and analysis {#Sec5}
--------------------------------

Isolation, culturing, and identification were conducted at each facility, and all sensitivity measurements were conducted at Kitasato University. To test sensitivity, the minimum inhibitory concentration (MIC) was measured using the broth microdilution method \[[@CR5]\] according to Clinical and Laboratory Standards Institute (CLSI) methods. Then, in accordance with the CLSI standards for oral antibacterial agents (nonmeningitis1, oral penicillin), PCG sensitivity of ≤0.06 μg/ml was classified as PSSP, sensitivity of 0.12--1.0 μg/ml was classified as PISP, and sensitivity of ≥2.0 μg/ml was classified as PRSP \[[@CR6]\].

In addition, strains from sterile sites accounted for less than 10 % of the overall strains, specifically 7 strains (blood) in period 3 and 24 strains in period 4 (cerebrospinal fluid, *n* = 1; blood, *n* = 23), and therefore no investigation by origin was conducted for them.

An analysis by patient background was also done to identify factors related to increased resistance. The analysis was done using the*χ*^2^ test with a two-sided significance level of 0.05. In cases when the expected value was ≤10, Fisher's exact probability test was used.

Results {#Sec6}
=======

Drug sensitivity {#Sec7}
----------------

The drug sensitivity results are shown in Table [1](#Tab1){ref-type="table"} for period 3 (2007) and in Table [2](#Tab2){ref-type="table"} for period 4 (2010).Table 1Drug susceptibility in period 3 (2007)DrugMIC range (μg/ml)*S. pneumoniae*PSSPPISPPRSPMIC~50~ (μg/ml)MIC~90~ (μg/ml)MIC~50~ (μg/ml)MIC~90~ (μg/ml)MIC~50~ (μg/ml)MIC~90~ (μg/ml)MIC~50~ (μg/ml)MIC~90~ (μg/ml)PCG≤0.063--20.251≤0.063≤0.0630.5122ABPC≤0.063--80.252≤0.063≤0.0631244AMPC≤0.063--40.251≤0.063≤0.0630.5114CCL0.125--1284640.541664128128CDTR≤0.063--40.1250.25≤0.0630.250.250.50.50.5CFPN≤0.063--80.250.50.1250.50.5111CPDX≤0.063--64120.2511224CFDN≤0.063--16140.2512448CTM≤0.063--8140.2512448CTRX≤0.063--80.2510.1250.50.5111CTX≤0.063--80.50.50.1250.50.5111CFTM≤0.063--80.2510.1250.50.5111AZM≤0.063--64\>64\>64\>64\>64\>64\>64\>64\>64CAM≤0.063 to \>64\>64\>6464\>64\>64\>64\>64\>64RKM≤0.063 to \>321\>322\>321\>32\>32\>32FRPM≤0.063--1≤0.0630.25≤0.063≤0.0630.250.250.50.5PAPM≤0.063--0.5≤0.063≤0.063≤0.063≤0.063≤0.0630.125≤0.0630.25MEPM≤0.063--0.5≤0.0630.25≤0.063≤0.0630.1250.250.50.5VCM0.125--0.50.250.250.250.250.250.250.250.25TEL≤0.063--1≤0.0630.25≤0.0630.25≤0.0630.250.1250.5LVFX0.5--211121112*ABPC* ampicillin, *AMPC* amoxicillin, *AZM* azithromycin, *CAM* clarithromycin, *CCL* cefaclor, *CDTR* cefditoren, *CFDN* cefdinir, *CFTM* cefteram, *CPDX* cefpodoxime, *CTM* cefotiam, *CTRX* ceftriaxone, *CTX* cefotaxime, *FRPM* faropenem, *LVFX* levofloxacin, *MEPM* meropenem, *PAPM* panipenem, *PCG* penicillin G, *PISP* penicillin-intermediate *S. pneumoniae*, *PRSP* penicillin-resistant *S. pneumoniae*, *PSSP* penicillin-susceptible *S. pneumoniae*, *RKM* rokitamycin, *TEL* telithromycin, *VCM* vancomycinTable 2Drug susceptibility in period 4 (2010)DrugMIC range (μg/ml)*S. pneumoniae*PSSPPISPPRSPMIC~50~ (μg/ml)MIC~90~ (μg/ml)MIC~50~ (μg/ml)MIC~90~ (μg/ml)MIC~50~ (μg/ml)MIC~90~ (μg/ml)MIC~50~ (μg/ml)MIC~90~ (μg/ml)PCG≤0.063--412≤0.063≤0.0630.5122ABPC≤0.063--80.52≤0.0630.1250.5224AMPC≤0.063--40.251≤0.063≤0.0630.25112PIPC≤0.063--40.52≤0.063≤0.0630.5222CCL≤0.063--128166412163264128CDTR≤0.063--80.2510.1250.50.250.50.51CFPN≤0.063--160.510.250.50.5112CPDX≤0.063--16120.521224CFDN≤0.063--32280.2512448CTM≤0.063--16180.250.51448CTRX≤0.063--80.510.250.50.5112CTX≤0.063--160.510.250.50.5112CFTM≤0.063--160.510.2510.5112AZM≤0.063 to \>64\>64\>64\>64\>64\>64\>64\>64\>64CAM≤0.063 to \>64\>64\>64\>64\>64\>64\>64\>64\>64RKM≤0.063--\>322\>328\>322\>322\>32FRPM≤0.063--10.1250.5≤0.063≤0.0630.1250.250.250.5PAPM≤0.063--0.5≤0.0630.125≤0.063≤0.063≤0.0630.125≤0.0630.25MEPM≤0.063--10.1250.5≤0.063≤0.0630.1250.250.250.5DRPM≤0.063--1≤0.0630.5≤0.063≤0.063≤0.0630.250.250.5TBPM≤0.063--0.125≤0.063≤0.063≤0.063≤0.063≤0.063≤0.063≤0.063≤0.063VCM≤0.063--0.50.250.50.250.50.250.50.250.5LVFX0.5--212121212TFLX≤0.063--0.50.250.250.250.250.250.250.250.25*ABPC* ampicillin, *AMPC* amoxicillin, *AZM* azithromycin, *CAM* clarithromycin, *CCL* cefaclor, *CDTR* cefditoren, *CFDN* cefdinir, *CFTM* cefteram, *CPDX* cefpodoxime, *CTM* cefotiam, *CTRX* ceftriaxone, *CTX* cefotaxime, *FRPM* faropenem, *LVFX* levofloxacin, *MEPM* meropenem, *PAPM* panipenem, *PCG* penicillin G, *PIPC* piperacillin*, PISP* penicillin-intermediate *S. pneumoniae*, *PRSP* penicillin-resistant *S. pneumoniae*, *PSSP* penicillin-susceptible *S. pneumoniae*, *RKM* rokitamycin, *TEL* telithromycin, *VCM* vancomycin

In period 3, 124 (43.8 %) strains were PSSP, 148 (52.3 %) strains were PISP, and 11 (3.9 %) strains were PRSP. PISP + PRSP accounted for 56.2 %. The best MIC~90~ of the antibacterial agents tested was for PAPM (≤0.063 μg/ml), followed by CDTR, FRPM, MEPM VCM, and TEL (0.25 μg/ml). By type of sensitivity, the MIC~90~ values of PCG, ABPC, AMPC, FRPM, PAPM, and MEPM were the most active for PSSP, at ≤0.063 μg/ml. PAPM had an MIC~90~ value of 0.125 μg/ml for PISP, and PAPM and VCM had MIC~90~ values of 0.25 μg/ml for PRSP.

In period 4, 106 (23.1 %) strains were PSSP, 229 (49.9 %) strains were PISP, and 124 (27.0 %) strains were PRSP. PISP + PRSP accounted for 76.9 %. The best MIC~90~ of the antibacterial agents tested was for TBPM (≤0.063 μg/ml), followed by PAPM (0.125 μg/ml). With respect to the MIC~90~ for PSSP, the best antibacterial agents were PCG, AMPC, PIPC, FRPM, TBPM, PAPM, MEPM, and DRPM, at ≤0.063 μg/ml. TBPM had the best MIC~90~ values for PISP and PRSP, at ≤0.063 μg/ml.

Resistance rates for each background factor {#Sec8}
-------------------------------------------

The resistance rates for background factors for the strains and the resistance rate with each background factor in periods 3 and 4 are shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}, respectively.Table 3Resistance rate for each background factor in period 3 (2007)Background factor*S. pneumoniae*PSSPPISPPRSPResistant rateStatistical testNumber of strainsNumber of strains (%)Number of strains (%)Number of strains (%)(%)Total283124 (43.8)148 (52.3)11 (3.9)56.2Sex Male14866 (44.6)78 (52.7)4 (2.7)55.4Fisher Female12453 (42.7)64 (51.6)7 (5.6)57.3*P* = 0.9537 Unknown115 (45.5)6 (54.5)0 (0.0)54.5Age category Infant5725 (43.9)30 (52.6)2 (3.5)56.1Fisher Toddler and preschooler20384 (41.4)110 (54.2)9 (4.4)58.6*P* = 0.0663 School child2215 (68.2)7 (31.8)0 (0.0)31.8 Unknown10 (0.0)1 (100.0)0 (0.0)100.0Siblings No12945 (34.9)76 (58.9)8 (6.2)65.1Fisher Yes15379 (51.6)71 (46.4)3 (2.0)48.4*P* = 0.0056 Unknown10 (0.0)1 (100.0)0 (0.0)100.0Daycare center attendee No11151 (45.9)58 (52.3)2 (1.8)54.1Fisher Yes15571 (45.8)75 (48.4)9 (5.8)54.2*P* = 0.0195 Unknown172 (11.8)15 (88.2)0 (0.0)88.2Daycare center attendee (siblings) No2512 (48.0)12 (48.0)1 (4.0)52.0*χ*^2^ Yes11663 (54.3)51 (44.0)2 (1.7)45.7*P* = 0.5663 Unknown14249 (34.5)85 (59.9)8 (5.6)65.5Previous antibacterial agents No12561 (48.8)58 (46.4)6 (4.8)51.2Fisher Yes15662 (39.7)89 (57.1)5 (3.2)60.3*P* = 0.2488 Unknown21 (50.0)1 (50.0)0 (0.0)50.0Penicillins Yes295 (17.2)21 (72.4)3 (10.3)82.8 Unknown254119 (46.9)127 (50.0)8 (3.1)53.1Cephems Yes10040 (40.0)57 (57.0)3 (3.0)60.0 Unknown18384 (45.9)91 (49.7)8 (4.4)54.1Macrolides Yes5328 (52.8)23 (43.4)2 (3.8)47.2 Unknown23096 (41.7)125 (54.3)9 (3.9)58.3*PISP* penicillin-intermediate *S. pneumoniae*, *PRSP* penicillin-resistant *S. pneumoniae*, *PSSP* penicillin-susceptible *S. pneumoniae*Table 4Resistance rate for each background factor in period 4 (2010)Background factor*S. pneumoniae*PSSPPISPPRSPResistant rateStatistical testNumber of strainsNumber of strains (%)Number of strains (%)Number of strains (%)(%)Total459106 (23.1)229 (49.9)124 (27.0)76.9Sex Male27265 (23.9)133 (48.9)74 (27.2)76.1Fisher Female18641 (22.0)95 (51.1)50 (26.9)78.0*P* = 0.7339 Unknown10 (0.0)1 (100.0)0 (0.0)100.0Age category Infant9821 (21.4)51 (52.0)26 (26.5)78.6*χ*^2^ Toddler and preschooler33071 (21.5)164 (49.7)95 (28.8)78.5*P* = 0.0256 Schoolchild3114 (45.2)14 (45.2)3 (9.7)54.8Siblings No18535 (18.9)96 (51.9)54 (29.2)81.1*χ*^2^ Yes27471 (25.9)133 (48.5)70 (25.5)74.1*P* = 0.0812Daycare center attendee No18044 (24.4)91 (50.6)45 (25.0)75.6Fisher Yes25155 (21.9)126 (50.2)70 (27.9)78.1*P* = 0.7893 Unknown287 (25.0)12 (42.9)9 (32.1)75.0Daycare center attendee (siblings) No4510 (22.2)26 (57.8)9 (20.0)77.8Fisher Yes20656 (27.2)98 (47.6)52 (25.2)72.8*P* = 0.1586 Unknown20840 (19.2)105 (50.5)63 (30.3)80.8Previous antibacterial agents No20451 (25.0)103 (50.5)50 (24.5)75.0*χ*^2^ Yes25555 (21.6)126 (49.4)74 (29.0)78.4*P* = 0.3861Penicillins Yes6013 (21.7)32 (53.3)15 (25.0)78.3 Unknown39993 (23.3)197 (49.4)109 (27.3)76.7Cephems Yes12729 (22.8)67 (52.8)31 (24.4)77.2 Unknown33277 (23.2)162 (48.8)93 (28.0)76.8Macrolides Yes10721 (19.6)50 (46.7)36 (33.6)80.4 Unknown35285 (24.1)179 (50.9)88 (25.0)75.9*PISP* penicillin-intermediate *S. pneumoniae*, *PRSP* penicillin-resistant *S. pneumoniae*, *PSSP* penicillin-susceptible *S. pneumoniae*

Looking at the background factors for 283 strains in period 3, ≥70 % of strains were from toddlers and preschoolers (71.7 %, 203 strains). Other background factors were being male (52.3 %, 148 strains), having siblings (54.1 %, 153 strains), daycare center attendee (54.8 %, 155 strains), and having previously received antibacterial agents (55.1 %, 156 strains). No significant differences were seen.

Of the background factors for 459 strains in period 4, the most were related to being male (59.3 %, 272 strains), being a toddler or preschooler (71.9 %, 330 strains), and having siblings (59.7 %, 274 strains). Other background factors were daycare center attendee (54.7 %, 251 strains) and having previously received antibacterial agents (55.6 %, 255 strains). However, no significant differences were seen.

In period 3, drug-resistant strains were related to daycare center attendance (*P* = 0.0195). In period 4, there were significantly more such strains by age category (*P* = 0.0256).

Discussion {#Sec9}
==========

Because penicillins have shown superior antibacterial activity against *S. pneumoniae*, refractory cases of pediatric respiratory tract infections have been rare. In recent years, however, PRSP that show resistance to penicillins, cephems, and carbapenems are increasing rapidly. The number of cases in which there is difficulty in treating acute otitis media or respiratory tract infections is growing, and the increasing drug resistance of *S. pneumoniae* is becoming a serious problem. \[[@CR4]\].

Surveillance of *S. pneumoniae* strains derived from pediatric infections was conducted to confirm the state of drug resistance increases in *S. pneumoniae* from October 2000 to July 2001 (period 1) and from January to June 2004 (period 2), and the findings were reported. Subsequent surveillance surveys were then conducted in period 3 and period 4.

The resistance rates were 56.2 % in period 3 and 76.9 % in period 4, more than half in both periods and showing an increasing trend. A rapid increase was seen in PRSP in particular, from 3.9 to 27.0 %. Investigation of the resistance rate by background factor revealed no common factors that showed significant differences in both period 3 and period 4, despite the significant differences seen with age category in periods 4 and 3, respectively. At the current time, no individual factor responsible for the increases in bacterial resistance can be identified.

However, PISP + PRSP accounted for 64.6 % in period 1, 66.9 % in period 2, 56.2 % in period 3, and 76.9 % in period 4, with a decrease in period 3. Looking at PRSP only, the proportions were 29.8, 29.8, 3.9, and 27.0 %, respectively, decreasing markedly in period 3.

Jaecklin et al. conducted a survey on patients under 16 years old in Switzerland \[[@CR7]\] and reported the isolation frequency of PISP + PRSP between 1989 and 2004. The isolation frequency, which was 2 % in 1989, maintained a 20 % level during the period after 1994 and reached 41 % in 2004. The trend observed in this survey was similar to that observed in the Japanese survey, although these surveys were conducted during different periods. Because pneumococci are becoming increasingly resistant to drugs around the world, close surveillance should be conducted continuously.

In a nationwide survey conducted by Suzuki et al. \[[@CR8]\] in the field of otorhinolaryngology, the isolation frequencies in 1994, 1998, 2003, and 2008 were 36.1, 29.1, 39.7, and 33.3 %, respectively, for PISP, 14.3, 21.8, 19.9, and 12.8 %, respectively, for PRSP, and 50.4, 50.9, 59.6, and 46.1 %, respectively, for PISP + PRSP. In 2008, marked decreases were seen in the proportions of PRSP and PISP + PRSP. Although there was a 1-year discrepancy in the years in which the surveys were conducted, these trends were similar to the present findings.

Clinical practice guidelines have been published one after another, including the "Guidelines for the Management of Respiratory Infectious Diseases in Children in Japan" \[[@CR9]\] in 2004, the "JRS Guidelines for the Management of Community-Acquired Pneumonia in Adults" \[[@CR10]\] in 2005, and the "Treatment Guidelines for Acute Otitis Media in Children" \[[@CR11]\]. The Guidelines for the Management of Respiratory Infectious Diseases in Children in Japan were revised in 2007 and 2011, and the Treatment Guidelines for Acute Otitis Media in Children were revised in 2009 for the edification of doctors and to encourage proper use of antibacterial agents, including new drugs. In addition, a *S. pneumoniae* vaccine for children put on the market in 2010 has been gradually changing the treatment of pediatric infections.

The results in this report may have been affected by the above-described change in clinical practice, and more detailed investigations are needed, for example, by drug use.

With regard to antibacterial sensitivity, drugs with an MIC~90~ ≤ 1 μg/ml for PRSP in period 3 and/or period 4 were CDTR, CFPN, CTRX, CTM, CFTM, FRPM, TBPM, PAPM, MEPM, DRPM, VCM, TEL, and TFLX. After excluding DRPM, TBPM, and TFLX, which were only measured in period 4 and TEL, which was only measured in period 3, only MEPM of the nine remaining drugs showed a greater than fourfold increase in MIC ~90~ from period 1 to period 4. *S. pneumoniae* is one of the major etiological agents in pediatric infections, and based on the sensitivity shown in this study, it is thought to be necessary to select antibacterial agents based on drug disposition and the administration route.

Ascertaining resistance status will lead not only to recommendations for appropriate antimicrobial treatment, but also to controlling drug-resistant pathogens, and we plan to continue conducting surveillance and providing information in the future.
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